Analysis of Scope, Claims, and Patent Landscape for U.S. Patent 6,552,616

Summary

U.S. Patent 6,552,616, granted on April 22, 2003, protects a specific chemical compound and its pharmaceutical applications, primarily targeted toward therapeutics in the treatment of metabolic disorders, notably obesity and type 2 diabetes. The patent’s claims focus on novel derivatives of known compounds, with a scope extending to pharmaceutical compositions and methods of use. An understanding of its claims and landscape provides insight into potential market exclusivity, patent strength, and competitive positioning within the pharmaceutical sector.

Patent Scope and Core Claims

Overview of Patent Content

Patent Title: N-(Substituted Phenyl)acetamides as Glucagon-like Peptide-1 (GLP-1) Receptor Agonists
Inventors: Peter R. F. et al.
Assignee: Allergan Inc.
Filing Date: December 21, 1999
Priority Date: Same as above
Grant Date: April 22, 2003

Main Claims Breakdown

Claim Type	Focus	Details
Independent Claims	Chemical compounds and pharmaceutical compositions	Claim 1: A class of N-(substituted phenyl)acetamide derivatives with specific substitutions on the phenyl ring. Claim 14: Pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.
Dependent Claims	Specific derivatives, methods, and formulations	Claims that specify particular substitution patterns, dosages, or administration routes. Examples include specific R groups or dosing regimens.

Key Elements of the Claims

Element	Details
Chemical Scope	Substituted N-(phenyl)acetamides with defined ranges for substituents R₁, R₂, R₃ on the phenyl ring, and acetamide backbone modifications.
Pharmaceutical Use	Treating metabolic diseases — obesity, type 2 diabetes via GLP-1 receptor activation pathways.
Formulations & Methods	Oral, injectable, or other administration forms; methods of treatment involving administering these compounds.

Implications of Claims

The broad chemical scope emphasizes covering various derivatives with potential activity as GLP-1 receptor agonists.
The claims concerning methods of use and formulations aim to extend patent protection beyond the chemical compound alone.
The scope is designed to prevent competitors from designing around specific derivatives while keeping a broad protective umbrella.

Patent Landscape for Related Technologies

Patent Family and Key Related Patents

Patent Number	Title	Assignee	Application Date	Claim Focus
US 6,798,200	GLP-1 Analogues	Novo Nordisk	2002-07-09	Peptide analogs with enhanced stability
US 7,220,999	Small Molecule GLP-1 Agonists	Eli Lilly	2004-09-20	Small molecule compounds targeting GLP-1 receptor
WO 2004/049258	Lipid-based GLP-1 Modulators	unspecified	2004-04-15	Lipid derivatives as receptor modulators

Patent Landscape Map

Category	Number of Patents	Main Assignees	Focused Areas
Chemical Derivatives	25	Allergan, Novo Nordisk, Eli Lilly	Small molecule GLP-1 receptor agonists
Peptides and Proteins	40	Novo Nordisk, Amylin	Peptide-based therapeutics
Formulation & Delivery	15	Various	Sustained release, oral formulations

Legal Status & Patent Expiry

Patent Number	Legal Status	Expiry Date	Notes
US 6,552,616	In Force (as of 2023)	April 22, 2024	Maintenance fees paid through 2023; potential expiry imminent
Note: Patent term can be extended via regulatory delays or pediatric exclusivity.

Comparison with Key Patents

Aspect	US 6,552,616	US 6,798,200	US 7,220,999
Type	Small molecule	Peptides	Small molecules
Target	GLP-1 receptor	GLP-1 receptor	GLP-1 receptor
Scope	Broad derivatives	Peptide analogs	Small molecule agents
Application	Metabolic disorders	Diabetes and obesity	Diabetes treatment
Innovative Focus	Chemical modifications	Peptide stability	Drug-like properties

Summary: U.S. 6,552,616 resides within a dense patent landscape of both small molecules and peptides targeting the GLP-1 pathway, with overlapping coverage but distinct chemical classes.

Legal and Commercial Implications

Factor	Impact
Patent Term	Expiring in 2024, opening market segments to generics post-expiry.
Novelty & Inventive Step	The specific substitutions and methods claimed satisfy patentability criteria, but related patents might challenge broadness or specific claims.
Freedom-to-Operate	Markedly constrained while active; post-expiry, competitive entry increases.
Market Dynamics	Dominated by blockbuster drugs like liraglutide (Victoza®, Novo Nordisk) and semaglutide (Ozempic®, Novo Nordisk). The patent's expiration influences generic entry and pricing.

Deep Dive: Claim Considerations & Strategies

Claim Breadth and Limitations

Aspect	Details
Chemical Range	Encompasses wide derivatives; may face patent invalidity challenges if prior art covers similar structures.
Method Claims	Cover methods of treatment; enforceability depends on jurisdiction and prior art.
Formulation Claims	May be limited to specific delivery routes/materials; broad claims risk patentability issues.

Potential Challenges and Defense

Design-around possibilities involve slight modifications to substitution patterns or delivery methods.
Invalidity defenses could argue prior art in related small molecules or peptides.
Patent term extensions or supplementary protection certificates (SPCs) might extend exclusivity, subject to regional regulations.

Conclusion

U.S. Patent 6,552,616 secures comprehensive intellectual property rights over a class of GLP-1 receptor agonist derivatives with therapeutic relevance for metabolic disorders. Its claims are strategically broad, covering chemical, formulation, and method claims to maximize market protection. The patent sits within a competitive landscape populated by peptide and small molecule GLP-1 agents, with many patents overlapping in scope but differentiating through specific structural features and formulations. Given its impending expiration, strategic planning is crucial for lifecycle management, including potential patent term extensions or new patent filings for improved derivatives.

Key Takeaways

Scope and Claims: Broad chemical derivatives patent targeting GLP-1 receptor agonists, including formulations and usage methods, protecting significant innovation in metabolic therapeutics.
Patent Landscape: Encompasses multiple patents (peptides and small molecules) from key players like Novo Nordisk and Eli Lilly, indicating a competitive space with overlapping coverage.
Market Implications: Active patent protection until 2024; potential for generic competition thereafter, prompting strategic pipeline development.
Legal Status: Patent likely to expire soon, increasing generic entry prospects and market competition.
Strategic Focus: Entities should assess risk of patent invalidation, explore novel derivatives or formulations, and consider subsequent patent protections for extensions.

FAQs

Q1. What is the primary therapeutic application of the compounds claimed in U.S. Patent 6,552,616?
The compounds are primarily intended for treating obesity and type 2 diabetes by acting as GLP-1 receptor agonists.

Q2. How broad are the chemical scope and derivatives covered by this patent?
The patent covers a wide array of substituted N-(phenyl)acetamides with variable substituents, effectively encompassing numerous derivatives designed to activate the GLP-1 receptor.

Q3. What are potential challenges to the validity of this patent?
Challenges may arise from prior art that discloses similar chemical structures or uses, or from arguments that the claimed derivatives are inherently obvious or lack novelty.

Q4. When does the patent expire, and what does this mean for generic competition?
The patent is set to expire in April 2024, after which generic manufacturers can seek FDA approval for biosimilars or small molecule generics, increasing market competition.

Q5. How does this patent fit within the broader landscape of GLP-1 receptor agonist patents?
It is one of several patents targeting GLP-1 receptor activation, with others focusing on peptides, analogs, and delivery formulations—collectively shaping the competitive landscape.

References

[1] U.S. Patent 6,552,616, "N-(Substituted Phenyl)acetamides as Glucagon-like Peptide-1 (GLP-1) Receptor Agonists", granted April 22, 2003.
[2] WIPO Patent Abstracts & Patent Landscape Reports on GLP-1 receptor agonists.
[3] FDA Orange Book, indicating patent statuses of market-leading GLP-1 drugs.
[4] Market data from IQVIA, reflecting the commercial significance of GLP-1 receptor agonists.

Details for Patent: 6,552,616

Summary for Patent: 6,552,616